Skip to Main Content
Upcoming Events / Biosimilars’ Meteoric Moment
  • Virtual

Biosimilars’ Meteoric Moment




{{getUserDateTimeZone("1665594000").time}} - {{getUserDateTimeZone("1665597600").time}} {{getClientTimeZoneName()}}


Like approaching asteroids, major biosimilars for Humira and other drugs are finally due to hit the market in 2023.

Should we brace for impact? How big of a crater will they make as doctors and patients react? A panel of experts will provide a forecast.


  • Madelaine A. Feldman, M.D., FACR, president, Coalition of State Rheumatology Organizations; clinical assistant professor of medicine, Tulane University School of Medicine
  • Steven Horvitz, president and founder, EMC Analytics Group
  • Darius Lakdawalla, Ph.D., director of research, USC Schaeffer Center for Health Policy & Economics; quintiles chair in pharmaceutical development and regulatory innovation, USC School of Pharmacy; professor, USC Price School of Public Policy
  • Michael Sherman, M.D., MBA, MS, executive vice president and chief medical officer, Point32Health
  • Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
  • Thomas Newcomer, head of US market access, Samsung Bioepis (sponsor speaker)

Register Now